(HealthDay News) -- In a long-awaited move, the U.S. Food and Drug Administration late Wednesday approved the blood thinner Brilinta (ticagrelor) for use in patients with acute coronary syndromes, to help lower their odds for heart attack and death.
Acute coronary syndromes include common conditions such as unstable angina or heart attack linked to lowered blood flow to the heart, the FDA noted in a statement. Brilinta, developed by pharmaceutical giant AstraZeneca, works to prevent new blood clots from forming.
The agency's move comes after a number of studies found that Brilinta performed well against the standard blood thinner now in use, Plavix (clopidogrel).
"In clinical trials, Brilinta was more effective than Plavix in preventing heart attacks and death, but that advantage was seen with aspirin maintenance doses of 75 to 100 milligrams once daily," Dr. Norman Stockbridge, director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.Read more...
Immunice for Immune Support
Many claims are being made about what one can do with Live Blood Analysis and this course will blow the trumpet of caution on several popular assumptions. That way you are going to end up with 1) a balanced view and 2) greater clinical confidence. By examining this topic in an comparative way from several angles you will get an excellent grasp of what is reasonable and above all what works in clinical practice!!
Subscribe to:
Post Comments (Atom)
Advanced Body Cleansing Kit$147.75 Advanced Body Cleansing Kit with Livatrex™, Oxy-Powder®, Latero-Flora™ and two bottles of ParaTrex®. |
No comments:
Post a Comment